Circassia cracks on with trials

Marion Dakers
CIRCASSIA, the newly-listed allergy drugs company, said yesterday its clinical trials are progressing as planned.

The firm expects results for two studies in the second half of the year and is pressing on with bringing its Cat-Spire treatment to market, it said in a trading update.

Circassia raised more than £200m when it floated on the main market of the London Stock Exchange in March with a view to funding its research programme.